{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:39:15Z","timestamp":1788273555300,"version":"build-2803163510"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Mayo Clinic Center for Clinical and Translational Science","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Hypothesis<\/jats:title>\n                  <jats:p>Teclistamab, a novel bispecific monoclonal antibody targeting CD3 and B cell maturation antigen (BCMA), and chimeric antigen receptor T cell (CAR-T) therapy are promising options for treating relapsed\/refractory multiple myeloma (MM). However, the rates of acute kidney injury (AKI) associated with teclistamab remain inadequately characterized. This study aims to compare the incidence, severity, and outcomes of AKI between patients receiving teclistamab and CAR-T therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a retrospective study involving 64 patients with relapsed\/refractory MM treated with either teclistamab or CAR-T therapy. All patients had previously received at least four lines of chemotherapy before being treated with either teclistamab or CAR-T. The primary outcome was the incidence of AKI, and secondary outcomes included AKI severity, kidney recovery rates, and mortality. Kaplan\u2013Meier estimates for AKI-free survival were calculated, and hazard ratios (HRs) for AKI risk were determined using Cox proportional hazards models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-four patients met inclusion criteria for this study (30 received CAR-T and 34 received teclistamab therapy). Among these patients, 14 AKI events occurred in total (22%), with 10 events (29%) in the teclistamab group and four events (13%) in the CAR-T group. AKI-free survival estimates at 180 days after treatment initiation were 68% [95% confidence interval (CI): 53%\u201387%] for teclistamab patients and 90% (95% CI: 79%\u2013100%) for CAR-T patients. While patients receiving teclistamab were found to have an increased risk of an AKI event compared to those receiving CAR-T therapy, the results were not statistically significant [HR (95% CI): 3.38 (0.93\u201312.31), P\u00a0=\u00a0.065].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study suggests that patients treated with teclistamab may experience a higher incidence of AKI compared to those receiving CAR-T therapy. However, further research is required to determine whether this increased risk is attributable to disease progression or teclistamab itself. These results highlight the need for close kidney function monitoring in patients receiving teclistamab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf004","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T21:52:28Z","timestamp":1736805148000},"page":"1512-1521","source":"Crossref","is-referenced-by-count":8,"title":["Incidence of acute kidney injury in relapsed and refractory multiple myeloma treated with teclistamab versus CAR-T cells"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-8796","authenticated-orcid":false,"given":"Mariam","family":"Charkviani","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose Vargas","family":"Brochero","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjunmohan","family":"Mohan","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Quantitative Health Sciences, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler B","family":"Sandahl","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre De Menezes Silva","family":"Corraes","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine , Rochester, MN ,","place":["USA"]},{"name":"Division of Hematology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"2025080112222626900_bib1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025080112222626900_bib2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"2025080112222626900_bib3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2025080112222626900_bib4","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/CMAR.S372237","article-title":"Teclistamab for multiple myeloma: clinical insights and practical considerations for a first-in-class bispecific antibody","volume":"15","author":"Pan","year":"2023","journal-title":"Cancer Manag Res"},{"key":"2025080112222626900_bib5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025080112222626900_bib6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"2025080112222626900_bib7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"2025080112222626900_bib8","article-title":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma"},{"key":"2025080112222626900_bib9","doi-asserted-by":"publisher","first-page":"e296\u2013","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"key":"2025080112222626900_bib10","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1200\/JCO.21.02558","article-title":"Summary of US Food and Drug Administration chimeric antigen receptor (CAR) T-cell biologics license application approvals from a statistical perspective","volume":"40","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025080112222626900_bib11","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/ndt\/gfr708","article-title":"The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients","volume":"27","author":"Smith","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025080112222626900_bib12","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2025080112222626900_bib13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025080112222626900_bib14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N Engl J Med"},{"key":"2025080112222626900_bib15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025080112222626900_bib16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"2025080112222626900_bib17","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2025080112222626900_bib18","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"2025080112222626900_bib19","doi-asserted-by":"publisher","first-page":"sfae027","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Le\u00f3n-Rom\u00e1n","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025080112222626900_bib20","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"2025080112222626900_bib21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41408-024-01023-9","article-title":"Adverse effects, and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study","volume":"14","author":"Gong","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025080112222626900_bib22","doi-asserted-by":"publisher","first-page":"1785\u201398","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis\u2014treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025080112222626900_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2024.09.017","article-title":"Diagnosis and management of Immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-nephrology","volume":"107","author":"Herrmann","year":"2025","journal-title":"Kidney Int"},{"key":"2025080112222626900_bib24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"2025080112222626900_bib25","article-title":"Common terminology criteria for adverse events (CTCAE)"},{"key":"2025080112222626900_bib26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025080112222626900_bib27","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf004\/61430215\/gfaf004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/8\/1512\/61430215\/gfaf004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/8\/1512\/61430215\/gfaf004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:22:31Z","timestamp":1754065351000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/8\/1512\/7953346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,1,13]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf004","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,1,13]]}}}